BridgeBio Pharma (NASDAQ:BBIO) reported first-quarter 2026 results highlighted by continued growth for ATTRUBY and increased investment to support three anticipated launches, while also announcing a ...

Primary results from CALIBRATE, the Phase 3 registrational clinical trial of encaleret, will be shared in an oral presentation at the 2026 European Congress of Endocrinology (ECE) on May 12, 2026 at ...

BridgeBio Pharma, Inc. remains a Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics. Learn more ...

BridgeBio Pharma stock snapshot after recent trading performance BridgeBio Pharma (BBIO) has drawn attention after recent trading, with the stock closing at US$68.78 and posting negative returns over ...

BridgeBio's Attruby launch crushed expectations, with Q1 revenue triple analyst estimates, driven by higher-than-expected conversion rates and minimal free trial usage. Competitive threats from ...

BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...

A BridgeBio Pharma drug developed for an increasingly prevalent cardiovascular condition has won FDA approval, marking a comeback for a company and a molecule with a turbulent history. But BridgeBio’s ...

CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes 1. PALO ALTO, ...

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

BridgeBio (BBIO) Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer of Transthyretin, or TTR, for the treatment of adults ...

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...